Review decision – January 2019

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on panobinostat for treating multiple myeloma in people who have received 1 prior therapy (TA380).

There has been no additional evidence identified that addresses the uncertainties in the guidance. The NICE guideline on myeloma (NG35) has recently been updated (October 2018). If this guideline is updated in future, the incorporation of this appraisal could be considered. 

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, TA380 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: